This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR (Aug 16): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Econpile Holdings Bhd, Apex Healthcare Bhd, Carlsberg Brewery Malaysia Bhd, Daibochi Bhd, Dialog Group Bhd, Hock Seng Lee Bhd, KPJ Healthcare Bhd, Sarawak Plantation Bhd, Sunway Construction Group Bhd and Warisan TC Holdings Bhd. Econpile Holdings Bhd secured a contract worth RM30.
APEXF KPJHF 5016 7090 6238 5878 5253 5263 2836 5135 7277
KUALA LUMPUR (Aug 16): KPJ Healthcare Bhd's net profit rose 31.6% to RM42.34 million in the second quarter ended June 30, 2018 (2QFY18) from RM32.17 million a year ago, on higher contribution from its Malaysia segment.
KPJ Healthcare Bhd (July 23, RM1.04) Maintain buy with a higher target price (TP) of RM1.30: KPJ’s Indonesia operations suffered the brunt of new healthcare policies, effectively capping prices for its healthcare services. 4QFY17 losses alone dragged group 4QFY17 operating earnings by -9%. However, with innovative and shrewd policies, we believe the worst is over for KPJ’s Indonesia operations. It should allay fears of further dragging.
KPJ Healthcare Bhd (June 8, RM1.10) Maintain buy with a target price (TP) of RM1.30: We maintain our positive stance on KPJ Healthcare Bhd post our meeting with management. Despite its recent share-price strength, we note that the stock is trading at 24 times financial year 2018 (FY18) earnings per share (EPS), which is around -1 standard deviation of its historical mean. Furthermore, the decent results for its first quarter of FY18 (1QFY18) reaffirm our investment thesis that the group’s operations are poised to pick up in FY18, as we expect the positive momentum to continue in the upcoming quarters.
KUALA LUMPUR: JF Apex Research expects CIMB, Hong Leong Bank, BIMB Holdings Bhd and Malaysian Resources Corp Bhd and MyEG Services Bhd to be among the stocks to watch following their latest corporate results.
KPJHF 5258 5878 5819 5102 7155 5112
2018-04-21 thestar.com.my - 1
Well equipped: A KPJ operating facility. KPJ digitises its clinical process through KCIS, which holds patient records and treatment orders, among others. Currently, the group is undergoing upgrading works for KCIS and HITS to second generation cloud-computing, which is expected to be completed by year-end.
Yasmin: The top challenges in digital readiness in key industries are the lack of structured approach, unavailable or no prioritised budget and a lack of digitally skilled workforce.
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...